Widening eligibility to phase II trials: constant arcsine difference phase II trialsA'HERN, Roger P.Controlled clinical trials. 2004, Vol 25, Num 3, pp 251-264, issn 0197-2456, 14 p.Article

A randomized, dose-finding, phase II study of the selective relaxant binding drug, sugammadex, capable of safely reversing profound rocuronium-lnduced neuromuscular blockGROUDINE, Scott B; SOTO, Roy; LIEN, Cynthia et al.Anesthesia and analgesia. 2007, Vol 104, Num 3, pp 555-562, issn 0003-2999, 8 p.Article

Phase II and pharmacokinetic study of aziridinylbenzoquinone [2,5-diaziridinyl-3,6-bis(carboethoxyamino)-1,4-benzoquinone, diaziquone, NSC 182986] in high-grade gliomas = Essai phase II et pharmacocinétique de l'aziridinylbenzoquinone [2,5-dioziridinyl-3,6-bis(carboéthoxyamino)-1,4-benzoquinone, diaziquone, NSC 182986] dans les gliomes de grade élevéCURT, G. A; KELLEY, J. A; KUFTA, C. V et al.Cancer research (Baltimore). 1983, Vol 43, Num 12, pp 6102-6105, issn 0008-5472Article

An early phase II trial with L-deprenyl for the treatment of neuroleptic-induced ParkinsonismPERENYI, A; BAGDY, G; ARATO, M et al.Pharmacopsychiatria. 1983, Vol 16, Num 5, pp 143-146, issn 0720-4280Article

Differential Roles of Phase I and Phase II Enzymes in 3,4-Methylendioxymethamphetamine-Induced CytotoxicityANTOLINO-LOBO, Irene; MEULENBELT, Jan; NIJMEIJER, Sandra M et al.Drug metabolism and disposition. 2010, Vol 38, Num 7, pp 1105-1112, issn 0090-9556, 8 p.Article

Novel Designs and End Points for Phase II Clinical Trials : Phase II Trials: Designs for the futureADJEI, Alex A; CHRISTIAN, Michaele; IVY, Percy et al.Clinical cancer research (Print). 2009, Vol 15, Num 6, pp 1866-1872, issn 1078-0432, 7 p.Article

A two-stage design for a phase II clinical trial of coenzyme Q10 in ALSLEVY, G; KAUFMANN, P; THOMPSON, J. L. P et al.Neurology. 2006, Vol 66, Num 5, pp 660-663, issn 0028-3878, 4 p.Article

Randomized phase II clinical trialsSIMON, R; WITTES, R. E; ELLENBERG, S. S et al.Cancer treatment reports. 1985, Vol 69, Num 12, pp 1375-1381, issn 0361-5960Article

Clinical drug development: an analysis of phase II trials, 1970-1985MARSONI, S; HOTH, D; SIMON, R et al.Cancer treatment reports. 1987, Vol 71, Num 1, pp 71-80, issn 0361-5960Article

Bimonthly leucovorin, infusion 5-fluorouracil, hydroxyurea, and irinotecan (FOLFIRI-2) for pretreated metastatic colorectal CancerMABRO, May; LOUVET, Christophe; ANDRE, Thierry et al.American journal of clinical oncology. 2003, Vol 26, Num 3, pp 254-258, issn 0277-3732, 5 p.Article

Safety and pharmacokinetics of plasma-derived mannose-binding lectin (MBL) substitution in children with chemotherapy-induced neutropaeniaFRAKKING, Florine N. J; BROUWER, Nannette; KUIJPERS, Taco W et al.European journal of cancer (1990). 2009, Vol 45, Num 4, pp 505-512, issn 0959-8049, 8 p.Article

Improving the design of phase II trials of cytostatic anticancer agentsSTONE, Andrew; WHEELER, Catherine; BARGE, Alan et al.Contemporary clinical trials. 2007, Vol 28, Num 2, pp 138-145, issn 1551-7144, 8 p.Article

A Phase II trial of vinorelbine tartrate in patients with disseminated malignant melanoma and one prior systemic therapy: A Southwest Oncology Group StudyWHITEHEAD, Robert P; MOON, James; MCCACHREN, S. Spence et al.Cancer. 2004, Vol 100, Num 8, pp 1699-1704, issn 0008-543X, 6 p.Article

Acceptability and adherence: findings from a Phase II study of a candidate vaginal microbicide, 'Praneem polyherbal tablet', in Pune, IndiaJOGLEKAR, N. S; JOSHI, S. N; DESHPANDE, S. S et al.Transactions of the Royal Society of Tropical Medicine and Hygiene. 2010, Vol 104, Num 6, pp 412-415, issn 0035-9203, 4 p.Article

Phase II study of daily oral perifosine in patients with advanced soft tissue sarcomaBAILEY, Howard H; MAHONEY, Michelle R; ETTINGER, David S et al.Cancer. 2006, Vol 107, Num 10, pp 2462-2467, issn 0008-543X, 6 p.Article

Samples of exact k-stage group sequential designs for Phase II and Pilot studiesKEPNER, James L; CHANG, Myron N.Controlled clinical trials. 2004, Vol 25, Num 3, pp 326-333, issn 0197-2456, 8 p.Article

PHASE II STUDY OF ANTINEOPLASTIC AGENTS IN JAPANMAJIMA H.1980; RECENT RESULTS CANCER RES.; DEU; DA. 1980; VOL. 70; PP. 61-65; BIBL. 7 REF.Conference Paper

Reversal of Profound, High-dose Rocuronium-induced Neuromuscular Blockade by Sugammadex at Two Different Time Points : An International, Multicenter, Randomized, Dose finding, Safety Assessor-blinded, Phase II TrialPUHRINGER, Friedrich K; REX, Christopher; SIELENKÄMPER, Andreas W et al.Anesthesiology (Philadelphia). 2008, Vol 109, Num 2, pp 188-197, issn 0003-3022, 10 p.Article

Safety and acceptability of the candidate microbicide Carraguard in Thai women : Findings from a phase II clinical trialKILMARX, Peter H; VAN DE WIJGERT, Janneke H. H. M; SUPAWITKUL, Somsak et al.Journal of acquired immune deficiency syndromes (1999). 2006, Vol 43, Num 3, pp 327-334, issn 1525-4135, 8 p.Article

Plans expérimentaux pour l'inclusion de patients dans les essais de phase II = Statisticals designs for phase II trialsKRAMAR, A; POTVIN, D; HILL, C et al.Revue d'épidémiologie et de santé publique. 1996, Vol 44, Num 4, pp 364-371, issn 0398-7620Article

Chemotherapy of diffuse malignant mesothelioma: phase II trials of single-agent 5-fluorouracil and adriamycinHARVEY, V. J; SLEVIN, M. L; PONDER, B. A. J et al.Cancer. 1984, Vol 54, Num 6, pp 961-964, issn 0008-543XArticle

Phase-II clinical trial of 4'-epi-doxorubicin in metastatic solid tumorsKOLARIC, K; POTREBICA, V; CERVEK, J et al.Journal of cancer research and clinical oncology. 1983, Vol 106, Num 2, pp 148-152, issn 0171-5216Article

Randomized Phase II Trials: Inevitable or Inadvisable?GAN, Hui K; GROTHEY, Axel; POND, Gregory R et al.Journal of clinical oncology. 2010, Vol 28, Num 15, pp 2641-2647, issn 0732-183X, 7 p.Article

A Comparison of Phase II Study StrategiesHUNSBERGER, Sally; YINGDONG ZHAO; SIMON, Richard et al.Clinical cancer research (Print). 2009, Vol 15, Num 19, pp 5950-5955, issn 1078-0432, 6 p.Article

Alternate Endpoints for Screening Phase II Studies : Phase II Trials: Designs for the futureDHANI, Neesha; DONGSHENG TU; SARGENT, DanielJ et al.Clinical cancer research (Print). 2009, Vol 15, Num 6, pp 1873-1882, issn 1078-0432, 10 p.Article